LIVIVO - Search results -

Search results

Result 1 - 10 of total 79

Search options

Article: Chronické podfinancování má zhoubný vliv na kvalitu nasí diagnostiky.

Fabian, Pavel

2014 Volume 50, Issue 3, Page(s) 110

Language	Czech
Publishing date	2014-07
Publishing country	Czech Republic
Document type	Interview
ZDB-ID	138273-1
ISSN	1210-7875 ; 0009-0611 ; 0371-1854
ISSN	1210-7875 ; 0009-0611 ; 0371-1854
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 897: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Gastrointestinal Polyposes and Lynch Syndrome - a Pathologists Perspective.

Pokorová, Šárka / Fabian, Pavel

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

2019 Volume 32, Issue Supplementum2, Page(s) 92–96

Abstract: Gastrointestinal polyposes and Lynch syndrome are a group of heterogenous hereditary tumor syndromes associated with an increased risk of developing colorectal carcinoma and other malignancies. Typical early manifestations of gastrointestinal polyposes ... ...

Title translation	Polypózy zažívacího traktu a Lynchův syndrom z pohledu patologa.
Abstract	Gastrointestinal polyposes and Lynch syndrome are a group of heterogenous hereditary tumor syndromes associated with an increased risk of developing colorectal carcinoma and other malignancies. Typical early manifestations of gastrointestinal polyposes include multiple polyps in the gastrointestinal tract. Early recognition of these syndromes enables patients carrying a pathogenic mutation to undergo screening and to instigate precautions to minimize the risk of developing tumors. In some cases, gastrointestinal lesions could be an early indicator of tumor syndrome and histopathologic examination could lead to a recommendation for genetic testing of patients and their families. Supported by Ministry of Health, Czech Republic - Conceptual Development of Research Organization (MMCI, 00209805). The authors declare they have no potential conflicts of interest concerning drugs, products,or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Submitted: 16. 4. 2019 Accepted: 6. 6. 2019.
MeSH term(s)	Gastrointestinal Neoplasms/diagnosis ; Gastrointestinal Neoplasms/genetics ; Gastrointestinal Neoplasms/pathology ; Humans ; Mutation ; Neoplastic Syndromes, Hereditary/diagnosis ; Neoplastic Syndromes, Hereditary/genetics ; Neoplastic Syndromes, Hereditary/pathology
Language	English
Publishing date	2019-08-12
Publishing country	Czech Republic
Document type	Journal Article
ZDB-ID	1217739-8
ISSN	1802-5307 ; 0862-495X
ISSN (online)	1802-5307
ISSN	0862-495X
DOI	10.14735/amko2019S92
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Primary Breast Sarcoma: A Two-Centre Analysis and Review of Literature.

Žatecký, Jan / Coufal, Oldřich / Fabian, Pavel / Holánek, Miloš / Sehnálková, Eva / Burkoň, Petr

Breast care (Basel, Switzerland)

2023 Volume 18, Issue 4, Page(s) 262–269

Abstract: Introduction: Primary breast sarcoma is a very rare malignant type of breast tumours with an incidence of 0.1% of all primary breast malignancies.: Methods: We present a retrospective analysis of the case series from two hospitals in the Czech ... ...

Abstract	Introduction: Primary breast sarcoma is a very rare malignant type of breast tumours with an incidence of 0.1% of all primary breast malignancies. Methods: We present a retrospective analysis of the case series from two hospitals in the Czech Republic with a review of the diagnostic and treatment approach to primary breast sarcomas with an analysis of published prognostic factors. Results: Eleven patients were included in the study, 9 women and 2 men. Statistical evaluation revealed that tumour size ( Conclusion: The analysis did not prove any of the factors, such as age, tumour size, grade, or mitotic activity, to be statistically significant prognostic factors. Based on the literature review, the most common published prognostic factors are tumour size, margin status, and grade, but the results are ambiguous.
Language	English
Publishing date	2023-05-12
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2202236-3
ISSN	1661-3805 ; 1661-3791
ISSN (online)	1661-3805
ISSN	1661-3791
DOI	10.1159/000530934
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6620: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Predikce odpovědi metastatického kolorektálního karcinomu na cílenou anti-EGFR léčbu.

Fabian, Pavel / Němeček, Radim

Ceskoslovenska patologie

2018 Volume 54, Issue 1, Page(s) 17–21

Abstract: The combination of modern systemic chemotherapy and anti-EGFR monoclonal antibodies improves overall survival and the quality of life for patients with metastatic colorectal cancer. By contrast, the addition of anti-EGFR therapy to the treatment regime ... ...

Title translation	Prediction of EGFR blockade responses in metastatic colorectal carcinoma.
Abstract	The combination of modern systemic chemotherapy and anti-EGFR monoclonal antibodies improves overall survival and the quality of life for patients with metastatic colorectal cancer. By contrast, the addition of anti-EGFR therapy to the treatment regime of resistant patients may lead to worse progression-free and overall survival. Therofore, identifying sensitive and resistant patients is key during initial decision-making. A number of clinical trials show that primary resistance to EGFR blockade is in most cases caused by constitutive activation of signalling pathways downstream of EGFR. Of the many biomarkers studied, only the KRAS and NRAS mutation status has reached clinical relevance in routine practice. The other markers (BRAF and PIK3CA mutations, PTEN and TP53 inactivation, EGFR and HER-2 amplification, epiregulin and amphiregulin overexpression, microRNA miR-31-3p and miR-31-5p etc.) still need to be validated. The accuracy of predictive diagnostic tools could also be increased by a combination of predictive markers on the next generation sequencing platform.
MeSH term(s)	Antibodies, Monoclonal ; Biomarkers, Tumor ; Class I Phosphatidylinositol 3-Kinases ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; ErbB Receptors/drug effects ; Humans ; Mutation ; Phosphatidylinositol 3-Kinases ; Proto-Oncogene Proteins B-raf ; Proto-Oncogene Proteins p21(ras) ; Quality of Life ; Receptor, ErbB-2
Chemical Substances	Antibodies, Monoclonal ; Biomarkers, Tumor ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; Class I Phosphatidylinositol 3-Kinases (EC 2.7.1.137) ; EGFR protein, human (EC 2.7.10.1) ; ERBB2 protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
Language	Czech
Publishing date	2018-04-09
Publishing country	Czech Republic
Document type	Journal Article
ZDB-ID	138273-1
ISSN	1210-7875 ; 0009-0611 ; 0371-1854
ISSN	1210-7875 ; 0009-0611 ; 0371-1854
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 897: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Role patologie v prediktivní onkologii solidních nádorů.

Fabian, Pavel

Casopis lekaru ceskych

2010 Volume 149, Issue 10, Page(s) 462–463

Abstract: Recently, a new generation of pharmacons that are aimed to hit specific molecular targets has entered the oncology. Currently, testing of tumour tissue for the presence of particular molecules is needed. Those molecular entities predict probability of ... ...

Title translation	The role of pathology in the predictive oncology of solid tumours.
Abstract	Recently, a new generation of pharmacons that are aimed to hit specific molecular targets has entered the oncology. Currently, testing of tumour tissue for the presence of particular molecules is needed. Those molecular entities predict probability of response to the targeted therapy. On a model of steroid hormone receptors and HER2 status testing a process of the predictive diagnostics is demonstrated. A contemporary concept of predictive oncology in the Czech Republic consisting of six "Predictive Oncology Laboratories" is described. Surgical pathology is shown as a key partner in the predictive oncology system.
MeSH term(s)	Breast Neoplasms/metabolism ; Breast Neoplasms/therapy ; Female ; Humans ; Molecular Targeted Therapy ; Neoplasms/metabolism ; Neoplasms/pathology ; Neoplasms/therapy ; Precision Medicine ; Prognosis ; Receptor, Epidermal Growth Factor/metabolism ; Receptor, ErbB-2/metabolism
Chemical Substances	Receptor, Epidermal Growth Factor (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
Language	Czech
Publishing date	2010
Publishing country	Czech Republic
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	413441-2
ISSN	1805-4420 ; 0008-7335
ISSN (online)	1805-4420
ISSN	0008-7335
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 278: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer.

Grell, Peter / Borilova, Simona / Fabian, Pavel / Selingerova, Iveta / Novak, David / Muller, Petr / Kiss, Igor / Vyzula, Rostislav

Cancers

2023 Volume 15, Issue 6

Abstract: Immune checkpoint inhibitors (ICI) are the main therapy currently used in advanced malignant melanoma (MM) and non-small cell lung cancer (NSCLC). Despite the wide variety of uses, the possibility of predicting ICI efficacy in these tumor types is scarce. ...

Abstract	Immune checkpoint inhibitors (ICI) are the main therapy currently used in advanced malignant melanoma (MM) and non-small cell lung cancer (NSCLC). Despite the wide variety of uses, the possibility of predicting ICI efficacy in these tumor types is scarce. The aim of our study was to find new predictive biomarkers for ICI treatment. We analyzed, by immunohistochemistry, various cell subsets, including CD3+, CD8+, CD68+, CD20+, and FoxP3+ cells, and molecules such as LAG-3, IDO1, and TGFβ. Comprehensive genomic profiles were analyzed. We evaluated 46 patients with advanced MM (31) and NSCLC (15) treated with ICI monotherapy. When analyzing the malignant melanoma group, shorter median progression-free survival (PFS) was found in tumors positive for nuclear FoxP3 in tumor-infiltrating lymphocytes (TILs) (
Language	English
Publishing date	2023-03-22
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers15061901
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Karcinomy prsu u nosiček mutací BRCA 1/2.

Fabian, Pavel / Nenutil, Rudolf

Ceskoslovenska patologie

2016 Volume 52, Issue 4, Page(s) 206–209

Abstract: Inherited mutations in BRCA1 and BRCA2 genes represent the most important cause of hereditary breast cancer. This highly penetrating familial cancer syndrome, including also the onset of ovarian cancer and other malignancies at relatively low age, ... ...

Title translation	Breast cancer in BRCA1/2 mutation carriers.
Abstract	Inherited mutations in BRCA1 and BRCA2 genes represent the most important cause of hereditary breast cancer. This highly penetrating familial cancer syndrome, including also the onset of ovarian cancer and other malignancies at relatively low age, represents a substantial medical problem. The affected families should be managed actively. When compared to spontaneous tumors, the breast carcinomas in BRCA1 mutation carriers exhibit a relatively different, despite non-specific, phenotype (often triple negative, medullary features) arousing suspicion of hereditary background. In the contrary, the distribution of phenotypes of breast carcinomas in BRCA2 carriers is similar to distribution in the non-affected population. The lymphocytic lobulitis is observed significantly more often in non-cancerous breast tissue of BRCA1/2 mutation carriers, but again, this feature is not specific.
Language	Czech
Publishing date	2016
Publishing country	Czech Republic
Document type	Journal Article ; English Abstract
ZDB-ID	138273-1
ISSN	1210-7875 ; 0009-0611 ; 0371-1854
ISSN	1210-7875 ; 0009-0611 ; 0371-1854
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 897: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer.

Kiss, David / Machackova, Tana / Souckova, Kamila / Fabian, Pavel / Krepelkova, Iveta / Svoboda, Marek / Kiss, Igor

In vivo (Athens, Greece)

2021 Volume 35, Issue 5, Page(s) 2809–2814

Abstract: Background/aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous ... ...

Abstract	Background/aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b-3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival (p=0.024). Conclusion: We have successfully confirmed miR-92b-3p to be up-regulated in tumor tissue of mCRC patients with good response to bevacizumab/FOLFOX therapy.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/therapeutic use ; Biomarkers ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Fluorouracil ; Follow-Up Studies ; Humans ; MicroRNAs/genetics ; Retrospective Studies
Chemical Substances	Biomarkers ; MicroRNAs ; Bevacizumab (2S9ZZM9Q9V) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2021-08-19
Publishing country	Greece
Document type	Journal Article
ZDB-ID	807031-3
ISSN	1791-7549 ; 0258-851X
ISSN (online)	1791-7549
ISSN	0258-851X
DOI	10.21873/invivo.12567
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2288: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?

Pokrivcak, Tomas / Lakomy, Radek / Kazda, Tomas / Poprach, Alexandr / Fabian, Pavel / Kiss, Igor

Medicine

2021 Volume 100, Issue 24, Page(s) e26381

Abstract: Rationale: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is ... ...

Abstract	Rationale: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is controversial and is the subject of a number of discussions due to the lack of randomized studies assessing individual treatment options. The adjuvant method of choice is surveillance or application of cisplatin-based chemotherapy with the risk of treatment related nephrotoxicity. Information about cisplatin safety in renal transplant patients is particularly limited. The aim of this paper is to share the experience with the application of adjuvant chemotherapy Bleomycin, Etoposide, Cisplatin (BEP) in high-risk patient with nonseminoma after kidney transplantation. Patient concerns: We report a case report of rare group of high-risk patient with non-seminomatous germ cell testicular tumor (NSGCT) after kidney transplantation before application of adjuvant chemotherapy BEP. Patient presented with month-long discomfort in the scrotal area. Previously, he was treated with chronic kidney disease based on chronic glomerulonephritis, which was treated with repeated kidney transplantation. Diagnosis: The ultrasound examination for a month-long discomfort in the scrotal area found a solid mass of the left testis. Radical inguinal orchiectomy confirmed NSGCT with the presence of lymphovascular invasion (LVI). Postoperative staging with computed tomography of the chest and abdomen did not show obvious dissemination of the disease. Interventions: Reducing original dose of chemotherapeutics according to the recommendations of the summary of product characteristics led to only a transient increase in creatinine levels. Outcomes: The 5-year risk of relapse in surveillance was reduced to around 3% by applying cisplatin-based chemotherapy. Lessons: Application of cisplatin-based chemotherapy is safe and effective in patients with CKD and in patients with a kidney transplant.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bleomycin/adverse effects ; Bleomycin/therapeutic use ; Chemotherapy, Adjuvant ; Cisplatin/adverse effects ; Cisplatin/therapeutic use ; Etoposide/adverse effects ; Etoposide/therapeutic use ; Humans ; Kidney Transplantation ; Male ; Middle Aged ; Neoplasms, Germ Cell and Embryonal/complications ; Neoplasms, Germ Cell and Embryonal/drug therapy ; Neoplasms, Germ Cell and Embryonal/surgery ; Orchiectomy ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/immunology ; Renal Insufficiency, Chronic/surgery ; Risk Assessment ; Testicular Neoplasms/complications ; Testicular Neoplasms/drug therapy ; Testicular Neoplasms/surgery
Chemical Substances	Bleomycin (11056-06-7) ; Etoposide (6PLQ3CP4P3) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2021-07-05
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	80184-7
ISSN	1536-5964 ; 0025-7974
ISSN (online)	1536-5964
ISSN	0025-7974
DOI	10.1097/MD.0000000000026381
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.171: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Epithelioid hemangioendothelioma on PET/CT scan.

Koukalová, Renata / Šedo, Jiří / Adámková, Dagmar Krákorová / Šimková, Zuzana / Fabian, Pavel / Szturz, Petr

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

2021 Volume 34, Issue 3, Page(s) 235–240

Abstract: Background: At present, lung cancer ranks among the most frequent malignant diseases. However, according to literature data, mesenchymal lung tumors are very rare, representing less than 0.5% of all malignant lung tumours. Epithelioid ... ...

Title translation	Epiteloidní hemangioendoteliom v PET/ CT obraze.
Abstract	Background: At present, lung cancer ranks among the most frequent malignant diseases. However, according to literature data, mesenchymal lung tumors are very rare, representing less than 0.5% of all malignant lung tumours. Epithelioid hemangioendothelioma of the lungs belongs to this group of uncommon entities. Case report: We present a case of a 45-year-old male with a history of increasing dyspnoea and abdominal and back pains, developing over the past several months. Vertebral lesions were found on imaging studies. PET/ CT following 18F-fluorodeoxyglucose administration (FDG) showed a large FDG-positive malignant infiltration affecting the thorax, abdominal cavity, and bones. The extension and other characteristics of the mass on PET/ CT did not correspond to any of the common oncologic diseases. With its spread in a plaque-like form predominantly in the right hemithorax and on the surface of the liver, the disease closely resembled malignant mesothelioma. The primary tumour origin could not be clearly identified on PET/ CT scans but they allowed us to choose a suitable site to obtain tissue for pathologic examination. Based on a CT-guided bone bio-psy of the 7th right rib, the dia-gnosis was concluded as epithelioid hemangioendothelioma. Despite an early initiation of systemic treatment, the patient succumbed to the disease only 15 days after the dia-gnosis, due to superior vena cava syndrome and progressive pleural effusion leading to respiratory insufficiency. Conclusions: Given the extremely low prevalence of epithelioid hemangioendothelioma and its heterogeneous manifestation, it is impossible to base the dia-gnosis solely on disease symptoms, laboratory findings, and imaging modalities. In this respect, pathologic examination has a crucial role. For the same reason, there is a lack of recommendations for the standard-of-care systemic therapy of metastatic disease.
MeSH term(s)	Fluorodeoxyglucose F18/metabolism ; Hemangioendothelioma, Epithelioid/diagnosis ; Hemangioendothelioma, Epithelioid/diagnostic imaging ; Hemangioendothelioma, Epithelioid/metabolism ; Humans ; Male ; Middle Aged ; Positron Emission Tomography Computed Tomography/methods ; Prognosis ; Radiopharmaceuticals/metabolism
Chemical Substances	Radiopharmaceuticals ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
Language	English
Publishing date	2021-07-15
Publishing country	Czech Republic
Document type	Case Reports ; Journal Article
ZDB-ID	1217739-8
ISSN	1802-5307 ; 0862-495X
ISSN (online)	1802-5307
ISSN	0862-495X
DOI	10.48095/ccko2021235
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito